BioXcel identifies 1.8M eligible patients and 86M episodes for IGALMI
BioXcel completed a market opportunity assessment for IGALMI’s at-home use, estimating 1.8 million eligible bipolar and schizophrenia patients and 86 million annual agitation episodes. The company advanced commercial plans and submitted an sNDA last month seeking FDA approval for outpatient acute agitation treatment.
1. Market Opportunity Assessment
The updated assessment combined 180 prescriber surveys, interviews with 15 prescribers and 5 payers, plus patient claims analysis to estimate 2.3 million treated bipolar and schizophrenia patients with frequent acute agitation in outpatient settings; up to 1.8 million patients may be eligible, representing 86 million addressable annual episodes.
2. Commercial Planning and sNDA Submission
BioXcel is advancing a comprehensive launch plan for IGALMI’s at-home use and submitted an sNDA last month seeking FDA approval for outpatient acute agitation treatment, targeting bipolar disorder and schizophrenia indications.
3. Prescriber and Payer Feedback
Prescribers indicated moderate to high interest, projecting IGALMI use in about 70% of agitation cases to replace benzodiazepines or off-label options; payers signaled expectations for broad formulary coverage with standard adjudication controls.